Ioflupane 123I
Title: Ioflupane 123I
CAS Registry Number: 155798-07-5
CAS Name: [1R-(exo,exo)]-8-(3-Fluoropropyl)-3-[4-(iodo123I)phenyl]-8-azabicyclo[3.2.1]octane-2-carboxylic acid methyl ester
Additional Names: N-(3-fluoropropyl)-2b-carbomethoxy-3b-(4-123I-iodophenyl)nortropane; methyl 8-(3-fluoropropyl)-3b-(p-iodo-123I-phenyl)-1aH,5aH-nortropane-2b-carboxylate; 123I-FP-CIT
Trademarks: DaTSCAN (GE Healthcare)
Molecular Formula: C18H23FINO2
Molecular Weight: 431.28
Percent Composition: C 50.13%, H 5.38%, F 4.41%, I 29.43%, N 3.25%, O 7.42%
Literature References: Analog of cocaine, q.v., that binds specifically to the dopamine transporters (DAT) in the membrane of the presynaptic dopaminergic neuron; designed as SPECT imaging agent to determine nigrostriatal neuronal integrity. Prepn: J. L. Neumeyer et al., US 5310912 (1994 to Research Biochemicals); idem et al., J. Med. Chem. 37, 1558 (1994). HPLC determn in biological fluids: K. A. Bergstroem et al., Hum. Psychopharmacol. 11, 483 (1996). Binding study: J. L. Neumeyer et al., J. Med. Chem. 39, 543 (1996). Clinical biodistribution: J. Booij et al., Eur. J. Nucl. Med. 25, 24 (1998). Clinical imaging for tremor differentiation: H. T. S. Benamer et al., Mov. Disord. 15, 503 (2000); for dementia differentiation: D. C. Costa et al., ibid. 18, Suppl. 7, S34 (2003). Functional imaging for dopaminergic deficit: H. T. S. Benamer et al., ibid. 18, 977 (2003). Clinical use in diagnosis of parkinsonism: A. M. Catafau et al., ibid. 19, 1175 (2004). Review of role in dopaminergic imaging: P. M. Kemp, Nucl. Med. Commun. 26, 87-96 (2005).
Properties: mp 82-83°. [a]D24 -12.8°.
Melting point: mp 82-83°
Optical Rotation: [a]D24 -12.8°
Therap-Cat: Diagnostic aid (radioactive imaging agent).
Keywords: Diagnostic Aid (Radioactive Imaging Agent).

Others monographs:
Magnesium SalicylateIndiplonp-Anisoyl ChlorideSabadine
Potassium PercarbonateBropirimine(4-Nitrophenyl)hydrazineEstragole
ChlorfenapyrDiazoacetic EsterLead BromateNickel Ammonium Sulfate
XipamideDroxicamOxalacetic AcidOxyphenbutazone
©2016 DrugLead US FDA&EMEA